<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 84 - Mims</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page83.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../index.html#p=84">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 84 - Mims</div>
        <div id="content-top2">P. 84</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../index.html#p=84"><img src="../thumb/84.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>74     TreaTmenT approaches



          Table 1. Bisphosphonates available in south Africa

           name           Dosage and route                 Indications
           alendronate    70 mg orally weekly              prevention of vertebral and nonverte-
                                                           bral fractures, including hip
           risedronate    35 mg orally weekly              prevention of vertebral and nonverte-
                          150 mg orally monthly            bral fractures, including hip
           Zoledronate    5 mg as iv infusion yearly       prevention of vertebral and nonverte-
                          must be well hydrated with normal serum   bral fractures, including hip
                          calcium level
           ibandronate    150 mg orally monthly            prevention of vertebral fractures
                          3 mg 3-monthly as iv injection



          causal relationship has not been proven. the risk   have been treated  with bisphosphonate for
          of aFF is very small, compared to the number of   severe osteoporosis.  the study also suggests
          typical femur neck fractures that are prevented   that  teriparatide  might  improve  acute  fracture
          by  bP therapy. In view of these complications,   healing.   because of cost consideration,
                                                        11
          noFSa recommends that after five years of   noFSa restricts the use of teriparatide to severe
          oral or three years of intravenous therapy, a   osteoporosis or failed treatment with other
          drug holiday of about the same time should be   medication. a recent opinion is that in new cases
          considered in the individual, if bMd has returned   of severe osteoporosis, optimal sequencing of
          to a t-score &gt;-2.5 and no fractures have occurred.   anabolic treatment is 18  months, followed by
          If the patient still remains at high risk of fracture,   antiresorptive treatment.
          alternative medication or continuation of bPs may   abaloparatide is a more selective form of PtH
          be considered.                          that is available in the uSa.
                                                    romosozumab is an anabolic agent available in
          denosumab                               the uSa. It is a humanised monoclonal antibody
          denosumab is a human monoclonal antibody   that inhibits sclerostin. It is administered as a
          that acts as a rank ligand inhibitor with inhibition   subcutaneous injection monthly for one year.
          of the development of osteoclasts.  denosumab
          prevents vertebral and non-vertebral fractures.     REfEREncEs
          a dose of 60 mg is administered subcutaneously   1.   Consensus development conference:  diagnosis
          six-monthly.  unlike  bPs, it is not dependent on   prophylaxis and treatment of osteoporosis.  Am J
          renal clearance. Incremental increase of bone-  Med. 1993;94:646-650.
          mineral density has been reported over 10 years,   2.   de  villiers  tJ.  bone health  and osteoporosis in
          along  with  a good  safety profile.  although  it  is   postmenopausal women.  Best Practice & Research
          advised by noFSa as first-line therapy, registration   Clinical Obstetrics and Gynaecology. 2009;23:73-85.
          in South  africa is still pending.  denosumab  is   3.   Cauley Ja, thompson de, ensrad KC, et al. risk of
          widely used in South  africa under Section 21   mortality following  clinical fractures.  Osteoporosis
          permission.                                Int. 2000;11:556-561.
                                                  4.   Johnell o, Kanis Ja. epidemiology of osteoporotic
          AnAbolic medicATion                        fractures. Osteoporosis Int. 2005;16:S3-S7.
          teriparatide  is  a  recombinant  protein form of   5.   Gullberg b, Johnell o, Kanis J. Worldwide projections
          parathyroid hormone. When given continuously   for hip fracture. Osteoporosis Int. 1997;7:407-413.
          as a daily subcutaneous injection of 20 ug for two   6.   burge  r,  dawson-Hughes  b, Solomon  dH,  et al.
          years, it reduces the risk of vertebral and non-  Incidence and economic burden of osteoporosis-
                                                     related fractures in the  united States, 2005-2025.
          vertebral fractures. the anabolic window lapses   J Bone Miner Res. 2007;22:465-475.
          after two years and should then be followed by   7.   dela t, Paruk F, brown S, et al. ethnic and gender-
          antiresorptive therapy. a recent study showed that   specific incidence rates for hip fractures in South
          the anti-fracture efficacy of teriparatide is superior   africa: a multi-centre study. Bone. 2020;133:115253.
          to that of risedronate in both osteoporosis,     8.   Kanis J, Harvey  n, Johansson H,  et al.  a decade
          treatment-naïve patients and in women who   of FraX: How has it changed the management


          MIMS ConCISe GuIde to CardIovaSCular, MetabolIC and endoCrIne dISeaSeS  VOLUME 1</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page83.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page79.html">79</a>&nbsp;&nbsp;&nbsp;<a href="page80.html">80</a>&nbsp;&nbsp;&nbsp;<a href="page81.html">81</a>&nbsp;&nbsp;&nbsp;<a href="page82.html">82</a>&nbsp;&nbsp;&nbsp;<a href="page83.html">83</a>&nbsp;&nbsp;&nbsp;<a href="page84.html">84</a>&nbsp;&nbsp;&nbsp;<a href="page85.html">85</a>&nbsp;&nbsp;&nbsp;<a href="page86.html">86</a>&nbsp;&nbsp;&nbsp;<a href="page87.html">87</a>&nbsp;&nbsp;&nbsp;<a href="page88.html">88</a>&nbsp;&nbsp;&nbsp;<a href="page89.html">89</a>
             </td>
             <td width="35%"><a href="page85.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page85.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
